On October 22, 2025, GSK plc announced positive Phase III data confirming therapeutic equivalence for a low carbon version of its salbutamol inhaler, potentially reducing greenhouse gas emissions by 92% per inhaler, with a global market of approximately 300 million units sold annually. The company plans to proceed with regulatory submissions and expects to launch by 2026.